Heth R. Turnquist
University of Nebraska Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Heth R. Turnquist.
European Journal of Immunology | 2000
Heth R. Turnquist; Heather J. Thomas; Kiley R. Prilliman; Charles T. Lutz; William H. Hildebrand; Joyce C. Solheim
To explore the nature of amino acid substitutions that influence association with TAP, we compared a site‐directed mutant of HLA‐B*0702 (Y116D) to unmutated HLA‐B7 in regard to TAP interaction. We found that the mutant had stronger association with TAP, and, in addition, with tapasin and calreticulin. These data confirm the importance of position 116 for TAP association, and indicate that (1) an aspartic acid at the 116 position can facilitate the interaction, and (2) association with tapasin and calreticulin is affected along with TAP. Furthermore, we tested three natural subtypes of HLA‐B15, and found that a B15 subtype with a tyrosine at position 116 (B*1510) was strongly associated not only with TAP, but also with tapasin and calreticulin. In contrast, two B15 subtypes with a serine at position 116 (B*1518 and B*1501) exhibited very little or no association with any of these proteins. Thus, very closely related HLA‐B subtypes can differ in regard to interaction with the entire assembly complex. Interestingly, when their surface expression was tested by flow cytometry, the HLA‐B15 subtypes with little to no detectable intracellular assembly complex association had a slightly, yet consistently, higher level of the open heavy chain form than did the B15 subtype with intracellular assembly complex association. These data suggest that the relatively low strength or short length of interaction between endoplasmic reticulum proteins and natural HLA class I molecules can decrease their surface stability.
Human Immunology | 2002
William H. Hildebrand; Heth R. Turnquist; Kiley R. Prilliman; Heather D. Hickman; Erin L. Schenk; Mary M. McIlhaney; Joyce C. Solheim
This article will describe coordinated analyses of how amino acid substitutions in the HLA class I antigen binding groove modify chaperone interaction and peptide ligand presentation. By parallel testing of ligand presentation and chaperone interaction with a series of natural HLA-B subtypes, this study has discovered that position 116 of the HLA-B15 class I heavy chain is pivotal in both peptide selection and control of interaction between the assembly complex and the class I heavy chain. Correlated with these qualitative differences in peptide selection and chaperone association are quantitative differences in the expression levels of the HLA molecules at the cell surface. These parallel studies, therefore, demonstrate that particular HLA class I polymorphisms can simultaneously influence ligand presentation and interaction with intracellular chaperones.
Transplantation | 2014
Brian R. Rosborough; Dàlia Raïch-Regué; Heth R. Turnquist; Angus W. Thomson
Regulatory myeloid cells (RMC) are emerging as novel targets for immunosuppressive (IS) agents and hold considerable promise as cellular therapeutic agents. Herein, we discuss the ability of regulatory macrophages, regulatory dendritic cells, and myeloid-derived suppressor cells to regulate alloimmunity, their potential as cellular therapeutic agents, and the IS agents that target their function. We consider protocols for the generation of RMC and the selection of donor- or recipient-derived cells for adoptive cell therapy. Additionally, the issues of cell trafficking and antigen (Ag) specificity after RMC transfer are discussed. Improved understanding of the immunobiology of these cells has increased the possibility of moving RMC into the clinic to reduce the burden of current IS agents and to promote Ag-specific tolerance. In the second half of this review, we discuss the influence of established and experimental IS agents on myeloid cell populations. IS agents believed historically to act primarily on T cell activation and proliferation are emerging as important regulators of RMC function. Better insights into the influence of IS agents on RMC will enhance our ability to develop cell therapy protocols to promote the function of these cells. Moreover, novel IS agents may be designed to target RMC in situ to promote Ag-specific immune regulation in transplantation and to usher in a new era of immune modulation exploiting cells of myeloid origin.
Clinical Cancer Research | 2002
Min Kim; Heth R. Turnquist; John D. Jackson; Magda Sgagias; Ying Yan; Maokai Gong; Michael Dean; John G. Sharp; Kenneth H. Cowan
Journal of Immunology | 1999
Yik Y. L. Yu; Heth R. Turnquist; Nancy B. Myers; Ganesaratnam K. Balendiran; Ted H. Hansen; Joyce C. Solheim
International Immunopharmacology | 2007
Abdelkader E. Ashour; Heth R. Turnquist; Rakesh K. Singh; James E. Talmadge; Joyce C. Solheim
Methods of Molecular Biology | 2000
Heth R. Turnquist; Joyce C. Solheim
Biochemical and Biophysical Research Communications | 2001
Heth R. Turnquist; Shanna E. Vargas; Joyce C. Solheim
Transplantation | 2017
Yifei Zhao; Hong Zhang; Lisa Mathews; Angus W. Thomson; Heth R. Turnquist
Transplantation | 2017
Gaelen K. Dwyer; Lisa Mathews; Anna Lucas; Bruce R. Blazar; Heth R. Turnquist